Medibiofarma announces the first subject dosed in the Phase Ib clinical trial of MBF-362 in cancer patients with solid tumours.
Navarra – December 2022 – Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new therapies for the treatment of cancer and non-cancer diseases announced the first subject...